Opus Genetics is trading 16.4% down at $2.90 in pre-market, extending a sharp pullback after its late-July rally.
- The move appears to be driven by traders locking in gains and repositioning following three strong up days, rather than any new fundamental catalysts.
- No fresh company-specific news, earnings, or major announcements have been identified to explain the double-digit decline, suggesting the drop is a normal consolidation phase.